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Abstract
Background: Human immunodeficiency virus (HIV) infection is very prevalent in Brazil. HIV therapy has been recently
associated with coronary heart disease (CHD). Dyslipidemia is a major risk factor for CHD that is frequently described
in HIV positive patients, but very few studies have been conducted in Brazilian patients evaluating their lipid profiles.
Methods: In the present work, we evaluated the frequency and severity of dyslipidemia in 257 Brazilian HIV positive
patients. Two hundred and thirty-eight (93%) were submitted to antiretroviral therapy (224 treated with protease
inhibitors plus nucleoside reverse transcriptase inhibitors, 14 treated only with the latter, 12 naive and 7 had no records
of treatment).
The average time on drug treatment with antiretroviral therapy was 20 months. None of the patients was under lipid
lowering drugs. Cholesterol, triglyceride, phospholipid and free fatty acids were determined by enzymatic colorimetric
methods. Lipoprotein profile was estimated by the Friedewald formula and Fredrickson's phenotyping was obtained by
serum electrophoresis on agarose. Apolipoprotein B and AI and lipoprotein "a" were measured by nephelometry.
Results: The Fredrickson phenotypes were: type IIb (51%), IV (41%), IIa (7%). In addition one patient was type III and
another type V. Thirty-three percent of all HIV+ patients presented serum cholesterol levels ≥  200 mg/dL, 61% LDL-
cholesterol ≥  100 mg/dL, 65% HDL-cholesterol below 40 mg/dL, 46% triglycerides ≥  150 mg/dL and 10% have all these
parameters above the limits. Eighty-six percent of patients had cholesterol/HDL-cholesterol ratio ≥  3.5, 22% increased
lipoprotein "a", 79% increased free fatty acids and 9% increased phospholipids. The treatment with protease inhibitors
plus nucleoside reverse transcriptase inhibitors increased the levels of cholesterol and triglycerides in these patients
when compared with naïve patients. The HDL-cholesterol (p = 0.01) and apolipoprotein A1 (p = 0.02) levels were
inversely correlated with the time of protease inhibitor therapy while total cholesterol levels had a trend to correlate
with antiretroviral therapy (p = 0.09).
Conclusion:  The highly varied and prevalent types of dyslipidemia found in Brazilian HIV positive patients on
antiretroviral therapies indicate the urgent need for their early diagnosis, the identification of the risk factors for CHD
and, when needed, the prompt intervention on their lifestyle and/or with drug treatment.
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Background
The prognosis of patients with acquired immune defi-
ciency syndrome (AIDS) was so limited until recently, that
the medical interest in other long term health problems
was irrelevant. The potency and sustained efficacy of the
highly active antiretroviral therapy (HAART) for treating
these patients brought a profound positive impact on
their life expectancy reducing their mortality rates from
AIDS [1].
Several reports [1-10] described the worsening of coro-
nary heart disease (CHD) and vascular atherosclerotic
complications in HIV+ patients after HAART therapy.
Recently, the DAD study (Data Collection on Adverse
Events of Anti-HIV Drugs) showed an increase in the risk
of myocardial infarction (MI) from 0.30% in patients
with no antiretroviral therapy to 1.07% in patients receiv-
ing these therapies, over a 3 year period [10].
Dyslipidemia is a major risk factor for the development of
CHD. It has also been reported that the AIDS infection
itself is capable of inducing dyslipidemia [11-14].
Hypertriglyceridemia was the first finding to be reported
in HIV-infected patients, but other lipid abnormalities
have also been described such as hypocholesterolemia,
hypobetalipoproteinemia, hypoalphalipoproteinemia
and, more rarely, hypercholesterolemia [11,13,15-17].
Brazil is the epicenter of the epidemic in South America
and accounts for three-fifths of reported AIDS cases and
57% in Latin America and Caribbean. Among the popula-
tion of high risk the prevalence is 42% [18].
Up to now two local studies [14,19] explored the dyslipi-
demia of Brazilian HIV+ patients but both in a small
number of cases.
Therefore the aim of this study was to determine the prev-
alence and severity of different types of dyslipidemia in a
large local HIV+ Brazilian population using antiretroviral
therapy. Serum lipids, lipoproteins and apolipoproteins
were measured and the effects on them of the viral load,
CD4 counting and duration of therapy were evaluated.
Methods
This study was approved by the Medical Ethics Committee
of the Medical Sciences Faculty of the University of
Campinas. Written consent was obtained from the
patients or their relative for publication of study.
Two hundred and fifty seven HIV+ patients were enrolled
in the protocol. They were attended in the Infectious Dis-
eases Clinic at the University of Campinas. Sixty-two per-
cent were men and 38% were women, with an average age
of 35 ± 8 years, body weight average 67 ± 13 Kg and body
mass indexes (BMI) 24 ± 4 Kg/m2. Two hundred and
thirty-eight (93%) were submitted to antiretroviral ther-
apy (224 treated with protease inhibitors plus nucleoside
reverse transcriptase inhibitors, 14 treated only with the
latter, 12 naïve and 7 had no records of treatment). The
average time on drug treatment with protease inhibitors
was 20 months (range 2 to 47 months). None of the
patients was under lipid lowering drugs and any other dis-
ease was described in their records.
The measurements of fasting serum cholesterol (Chol),
HDL-cholesterol (HDL-chol) and triglycerides (TG) were
obtained by enzymatic colorimetric methods (automated
Mega-Bayer system). The LDL-cholesterol (LDL-chol) and
VLDL-cholesterol (VLDL-chol) were estimated by Friede-
wald's equation. In patients with triglyceride levels above
400 mg/dL (n = 16), Friedwald's equation was not used.
The apolipoproteins A1 (Apo A1), B100 (Apo B) and lipo-
protein "a" [Lp (a)] were measured by nephelometric
methods (semi-automated Beckman Array-360 system)
[20]. Free fatty acids (FFA) and phospholipids (PL) were
determined by enzymatic colorimetric methods (Wako
Chemicals GmbH, Japan). The plasma lipoproteins were
fractioned by agarose gel electrophoresis (Paragon Elec-
trophoresis System – Beckman, Ca, USA). The bands were
carefully analyzed by visual inspection [21]. Apo E geno-
typing was performed by PCR assay [21] in 3 cases sus-
pected of type III phenotype.
In a sub-group of patients presenting Chol and/or TG,
respectively equal to or above 200 and 150 mg/dL (n =
141), the criterion for describing the dyslipidemia was in
accord with WHO/ Fredrickson's classification [22].
The lipid profiles were analyzed using the values recom-
mended by the National Cholesterol Education Program
(NCEP, 2001) [23]. The desirable Chol/HDL-chol ratio
was lower than 3.5 [24] and was used as an CHD risk
index.
The reference intervals for apolipoproteins, Lp (a), PL and
FFA were obtained from the manufacturers' recommenda-
tions. Apo A1: 94–178 mg/dL and 101–199 mg/dL; Apo
B100: 52–109 mg/dL and 40–103 mg/dL for men and
women, respectively; Lp(a) below 30 mg/dL; PL: 150–250
mg/dL and FFA: 0.1–0.6 mEq/L.
Immunologic evaluation included measurements of lym-
phocyte sub-populations, CD4 and CD8, by flow citome-
try and the determination of the viral load by PCR.
Kruskal-Wallis with post test Dunn was employed to com-
pare the lipidic parameter averages between the 2 groups
of antiretroviral therapy users and between the treatedBMC Infectious Diseases 2005, 5:47 http://www.biomedcentral.com/1471-2334/5/47
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groups and naïve patients. Ancova and Pearson's tests
were employed to correlate lipid profiles and CD4 cells,
viral load and time of use of protease inhibitors. BMI, age
and gender were chosen as covariates. Differences were
considered significant when p ≤  0.05.
Results
The patients were classified according to the Center for
Disease Control (CDC) -1993 [25] as follows: stage A,
39.3%; stage B, 12.4%; stage C, 45.6% (44.0% belonging
to the clinical C3 category) and 2.7% were not clinically
defined. There was an inversion of CD4 counting (average
337 cells/mm3) and CD8 counting (average 947 cells/
mm3) that may be explained by the fact that approxi-
mately 44% of the patients belonged to the C3 category.
Forty-four percent of the patients who had their viral load
measured presented less than 400 copies/mL, 29%
between 400–10,0000 copies/mL and 27% above 10,000
copies/mL.
Fifty-five percent of total HIV+ population (141 patients)
was selected by their high Chol and/or TG levels for fur-
ther serum electrophoresis analysis. In eighteen patients
the electrophoresis were not done and in 20 patients the
results were inconclusive. The most frequent patterns
according to Fredrickson's classification were type IV
(41%) and IIb (51%) (Table 1). One patient was type III,
another one type V and seven IIa.
Patients' lipid, lipoprotein and apolipoprotein profiles
are reported in Table 2. Figure 1 shows the percent distri-
bution of HIV+ patients according to the NCEP (2001)
classification [23]. Thirty-three percent of total HIV+
patients had Chol levels ≥  200 mg/dL, 65% had HDL-chol
below 40 mg/dL, 61% had LDL-chol ≥  100 mg/dL; 46%
had triglycerides ≥  150 mg/dL and 86% had the choles-
terol/HDL-chol ratio ≥  3.5. Seventy-nine percent of the
patients presented FFA values above the maximum refer-
ence value of 0.6 mEq/L. The average serum concentration
of PL and Lp(a) were within the reference limits. However,
22% of the patients had Lp(a) above 30 mg/dL and 9%
had PL above 250 mg/dL.
Table 1: Percentual distribution of HIV+ patients according to WHO/Fredrickson classification in total HIV+ patients.
Type Percent of dyslipidemic patients* (n = 103) Percent of the total HIV+ population (n = 257)
IIa 7 3
IIb 51 20
III 1 0,4
IV 41 16
V1 0 , 4
*Patients with chol and/or TG respectively, >200 and >150 mg/dL, were classified based on Fredrickson's classification
Table 2: Serum lipid, lipoprotein and apolipoprotein profiles in HIV+ patients (n = 257)
Variablesa Mean ± SD Minimum Maximum
Chol 185 ± 55 68 672
TG 192 ± 179 36 1512
HDL-chol 36 ± 12 12 73
LDL-chol* 112 ± 38 10 227
VLDL-chol* 31 ± 16 7 79
PL 192 ± 72 94 702
FFA 1.2 ± 0.75 0.10 6.3
Apo A1 121 ± 28 29 291
Apo B 88 ± 26 37 173
Lp(a) 21 ± 24 1 124
Chol/HDL-chol 5.6 ± 3 2 39.5
aData expressed as mg/dL and FFA as mEq/L. * n = 241 patientsBMC Infectious Diseases 2005, 5:47 http://www.biomedcentral.com/1471-2334/5/47
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Lipid frequency distribution patterns in HIV+ patients (n = 236 to 257) according to NCEP's recommendations Figure 1
Lipid frequency distribution patterns in HIV+ patients (n = 236 to 257) according to NCEP's recommendations.
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The mixed dyslipidemia in HIV+ patients are widely dis-
tributed and the frequency varied from 13% for TG or
Chol + LDL-chol + HDL-chol to 38% for Chol+TG+HDL-
chol.
The treatment with protease inhibitors plus nucleoside
reverse transcriptase inhibitors increased significantly
Chol and TG levels (p < 0.05) in these patients when com-
pared to naïve HIV+ patients (187 ± 55 vs 150 ± 21 mg/dL
and 199 ± 187 vs 106 ± 51 mg/dL for Chol and TG, respec-
tively), no differences were found between the two drugs
groups.
There was a significant negative correlation (Figure 2)
between the time of protease inhibitors (PI) therapy and
HDL-chol (r = -0.214) and Apo A1 (r = -0.154) levels (p =
0.01 and p = 0.02, respectively). Also a significant negative
association (p = 0.03) was found between Chol levels and
the viral load. Total cholesterol levels have a trend to be
associate with protease inhibitor therapy (p = 0.09).
Discussion
Dyslipidemia using the WHO/Fredrickson classification
in a Brazilian HIV+ patients is examined here for the first
time.
Schmidt et al [25] described dyslipidemia in 57% of 98
HIV+ individuals treated with protease inhibitors and
found a different prevalence from our group: phenotypes
IV and V were more frequent than IIb and IIa. Maus et al
[26] just recently presented this classification in 187
treated German HIV+ individuals. Some curious differ-
ences were found between the phenotyping of the 2 pop-
ulations: types IIb and IV was equally frequent in our
study, but the German group type IV was the predominant
one.
The data presented here are alarming. A very high preva-
lence of different types of dyslipidemia was found in the
population of 257 HIV+ patients: 33% showed increased
cholesterol, 46% increased triglycerides, decreased HDL-
cholesterol level in 65%, cholesterol/HDL-chol ratio ≥  3.5
in 86%, increased LDL-cholesterol in 61%, increased
Lp(a) in 22%, increased free fatty acids in 79% and
increased phospholipids in 9%. All of these profiles are
strongly related to CHD risk.
In this study we showed that in patients using antiretrovi-
ral therapy there was an augment in the concentrations of
plasma cholesterol and triglycerides when compared to
naïve patients. We also found negative associations
between the time on PI therapy and HDL-chol and Apo
A1 levels and a trend to a positive correlation between the
viral load and cholesterol levels.
Although HIV infection itself has been associated with
altered lipid metabolism, substantial evidence indicates a
role for some protease inhibitors and reverse transcriptase
inhibitors in causing metabolic complications [27-32].
Many adverse reactions can be attributed to protease
inhibitors, however; because several treatments use drug
association regimens, it is difficult to find out the exact
causal connection [33].
Several reports have associated hypertriglyceridemia with
the use of antiretroviral therapy [6,8,30,33-37]; however,
the increase in triglyceride levels was also described in
HIV+ patients before the utilization of HAART [11,38].
Hypertriglyceridemia was highly prevalent in our and
other studies [6,11-13,36,38-43]. This may also be sec-
ondary to cytokine production. Cytokines have been
shown to increase hepatic lipid synthesis and/or decrease
levels of lipoprotein lipase, which results in slower
Correlations between time on protease inhibitor therapy  and HDL-chol, (panel A) and Apo A 1 (panel B) Figure 2
Correlations between time on protease inhibitor therapy 
and HDL-chol, (panel A) and Apo A 1 (panel B).
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clearance of circulating triglyceride-rich particles [44].
Grunfeld et al [44] found a highly significant positive cor-
relation between interferon-α  and triglyceride levels. In
our study, hypertriglyceridemia was present in 46% per-
cent of the HIV+ patients. Thirty-six percent of the
patient's hyperlipoproteinaemia was due to types IV and
IIb (Table 3). The origin of the hypertrygliceridemia could
be an increased hepatic VLDL-TG secretion rate, with high
availability of FFA to the liver, secondary to insulin resist-
ance, common in these patients [45,46]. Seventy nine per-
cent of our patients presented high plasma levels of FFA,
corroborating with this metabolic state.
We did not find significant correlations between triglycer-
ides and viral load [16], CD4 levels [13,40] and the type
of antiretroviral therapy [35], but we did find negative cor-
relation between the duration of treatment with PI and
HDL-chol (p = 0.01).
Low HDL-Chol was one of the major findings in this Bra-
zilian HIV+ population (65%). These findings are in
accordance with several authors [13,35,42]. Several meta-
bolic processes may contribute to these low HDL levels:
decrease in free cholesterol removal from cells, low cho-
lesterol esterification rate and high cholesteryl ester trans-
fer from HDL to apo-B containing lipoproteins [47].
Hypercholesterolemia was very prevalent in the dyslipi-
demic individuals described here: 58% are types IIa and
IIb. Grunfeld et al.[44] didn't find significant differences
in the cholesterol levels of patients affected by HIV: HIV+;
HIV+ with AIDS or HIV negative, but Law et al. found
raised cholesterol and triglyceride levels in patients receiv-
ing HAART, compared with patients not receiving HAART
[10]. Our results are in agreement with Law's paper.
Grunfeld et al [39] showed a significant decrease in cho-
lesterol levels in the HIV+ and HIV+ with AIDS patients,
when compared to HIV- subjects. Shor-Posner et al [48]
observed hypocholesterolemia (chol <150 mg/dL) in
41% of HIV+ and in 17% of HIV- patients. Christeff et al
[40] reported decreased concentrations of cholesterol and
phospholipids in HIV+ patients, except in those with low
CD4 counting (400–150 cells/mm3). In this study, 29%
of the patients presented hypocholesterolemia. We found
an inverse correlation between plasma cholesterol levels
and the viral load.
The observed high frequency of hypercholesterolemia and
hyperbetalipoproteinemia in HIV+ Brazilian patients
were never reported previously (Table 1, Figure 1). Also
analyzing the various patterns of the combined hyperlipi-
demia the most prevalent were alterations in TG plus
HDL-chol and LDL-chol plus HDL-chol, respectively 35
and 32% ; total cholesterol plus TG and HDL-chol in 38%
and 11% of patients had four different lipidic parameters
altered.
Conclusion
The high frequency of phenotypes IIb and IV found in the
Brazilian HIV positive patients and the severity of the dis-
turbances such as: hypercholesterolemia up to 672 mg/
dL, hyperbetalipoproteinemia up to 227 mg/dL, hyper-
triglyceridemia up to 1512 mg/dL and hypoalphalipopro-
teinemia below 13 mg/dL, indicate the urgent need for
their early diagnosis, the identification of the presence of
other risk factors for CHD and, when needed, the prompt
intervention on their lifestyle and/or drug treatment
[49,50].
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